These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32881242)

  • 1. Exploration of CTNNB1 ctDNA as a putative biomarker for hepatoblastoma.
    Kahana-Edwin S; McCowage G; Cain L; Saletta F; Yuksel A; Graf N; Karpelowsky J
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28594. PubMed ID: 32881242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
    Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
    BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors.
    Yamaoka H; Ohtsu K; Sueda T; Yokoyama T; Hiyama E
    Oncol Rep; 2006 Mar; 15(3):551-6. PubMed ID: 16465411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.
    Campani C; Imbeaud S; Couchy G; Ziol M; Hirsch TZ; Rebouissou S; Noblet B; Nahon P; Hormigos K; Sidali S; Seror O; Taly V; Ganne Carrie N; Laurent-Puig P; Zucman-Rossi J; Nault JC
    Gut; 2024 Oct; 73(11):1870-1882. PubMed ID: 39054058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.
    Lee H; El Jabbour T; Ainechi S; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon SH; Ali SM; Schrock A; Fabrizio D; Frampton G; Nazeer T; Miller VA; Stephens PJ; Ross JS
    Hum Pathol; 2017 Dec; 70():84-91. PubMed ID: 29079173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
    Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
    Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
    Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
    Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel tissue-based ß-catenin gene and immunohistochemical analysis to exclude familial adenomatous polyposis among children with hepatoblastoma tumors.
    Dubbink HJ; Hollink IHIM; Avenca Valente C; Wang W; Liu P; Doukas M; van Noesel MM; Dinjens WNM; Wagner A; Smits R
    Pediatr Blood Cancer; 2018 Jun; 65(6):e26991. PubMed ID: 29446530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HGF/c-Met related activation of β-catenin in hepatoblastoma.
    Purcell R; Childs M; Maibach R; Miles C; Turner C; Zimmermann A; Sullivan M
    J Exp Clin Cancer Res; 2011 Oct; 30(1):96. PubMed ID: 21992464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).
    Jilg S; Rassner M; Maier J; Waldeck S; Kehl V; Follo M; Philipp U; Sauter A; Specht K; Mitschke J; Lange T; Bauer S; Jost PJ; Peschel C; Duyster J; Gaiser T; Hohenberger P; von Bubnoff N
    Int J Cancer; 2019 Oct; 145(8):2292-2303. PubMed ID: 30882891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma.
    Egyud M; Tejani M; Pennathur A; Luketich J; Sridhar P; Yamada E; Ståhlberg A; Filges S; Krzyzanowski P; Jackson J; Kalatskaya I; Jiao W; Nielsen G; Zhou Z; Litle V; Stein L; Godfrey T
    Ann Thorac Surg; 2019 Aug; 108(2):343-349. PubMed ID: 31059681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
    Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
    J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma.
    Jiang P; Sun K; Tong YK; Cheng SH; Cheng THT; Heung MMS; Wong J; Wong VWS; Chan HLY; Chan KCA; Lo YMD; Chiu RWK
    Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10925-E10933. PubMed ID: 30373822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.
    von Felden J; Craig AJ; Garcia-Lezana T; Labgaa I; Haber PK; D'Avola D; Asgharpour A; Dieterich D; Bonaccorso A; Torres-Martin M; Sia D; Sung MW; Tabrizian P; Schwartz M; Llovet JM; Villanueva A
    Oncogene; 2021 Jan; 40(1):140-151. PubMed ID: 33097857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of glutamine synthetase and cytochrome P450 isoforms in human hepatoblastoma.
    Schmidt A; Braeuning A; Ruck P; Seitz G; Armeanu-Ebinger S; Fuchs J; Warmann SW; Schwarz M
    Toxicology; 2011 Mar; 281(1-3):7-14. PubMed ID: 21237236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current status of diagnosis and treatment of hepatoblastoma].
    García-Miguel P; López Santamaría M
    Clin Transl Oncol; 2005 Aug; 7(7):328-34. PubMed ID: 16185597
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.